News|Videos|March 6, 2025
The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions
Author(s)Joyce O’Shaughnessy, MD, Alison Conlin, MD
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Conlin to Dr. O’Shaughnessy: Looking ahead, how do you see the treatment landscape evolving?
- What impact might the SERENA-6 trial have on sequencing practices (
Turner et al. Future Oncology 2023 )? - What mechanisms of resistance to PI3K/AKT pathway inhibitors or oral SERDs do you anticipate?
- What unmet needs remain to be addressed?
- What impact might the SERENA-6 trial have on sequencing practices (
Advertisement
Related to this article
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5